Clinical Characteristics and Outcomes in Patients With KRAS G12C Mutated Non-Small Cell Lung Cancer

被引：0
|
作者：
Pellini, B. [1 ]
Ganesan, V. [2 ]
Wan, F. [3 ]
Sankararaman, S. [4 ]
Manyanont, S. [4 ]
Akhave, N. [5 ]
Baggstrom, M. [4 ]
Ward, J. [4 ]
Waqar, S. [4 ]
Morgensztern, D. [4 ]
Govindan, R. [6 ]
Devarakonda, S. [4 ]
机构：
[1] H Lee Moffitt Canc Ctr & Res Inst, Dept Thorac Oncol, Tampa, FL USA
[2] Univ Missouri, Sch Med, Kansas City, MO 64108 USA
[3] Washington Univ, Sch Med, Div Publ Hlth Sci, St Louis, MO 14263 USA
[4] Washington Univ, Sch Med, Div Oncol, St Louis, MO USA
[5] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[6] Siteman Canc Ctr, St Louis, MO USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 03期
关键词：
Non-small cell lung cancer; KRAS G12C mutation; KRAS-mutant NSCLC;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
FP07.13
引用
收藏
页码：S209 / S210
页数：2
相关论文
共 50 条
  • [21] The MET Inhibitor Tepotinib Potentially Inhibits KRAS G12C and SHOC2 in KRAS G12C Non-Small Cell Lung Cancer (NSCLC)
    Rosell, R.
    Jain, A.
    Codony-Servat, J.
    Shivamallu, C.
    Kollur, S. Prasad
    Prasad, A.
    Jantus-Lewintre, E.
    Ito, M.
    Cardona, A. F.
    Arrieta, O.
    Cao, P.
    Cai, X.
    Xing, B.
    Pedraz-Valdunciel, C.
    Dantes, Z.
    Sullivan, I.
    Aguilar, A.
    Molina-Vila, M. A.
    Gonzalez-Cao, M.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S112 - S112
  • [22] Concomitant KRAS mutations attenuate sensitivity of non-small cell lung cancer cells to KRAS G12C inhibition
    Tereza Vaclova
    Atanu Chakraborty
    James Sherwood
    Sarah Ross
    Danielle Carroll
    J. Carl Barrett
    Julian Downward
    Elza C. de Bruin
    Scientific Reports, 12
  • [23] Sotorasib: A Review in KRAS G12C Mutation-Positive Non-small Cell Lung Cancer
    Lee, Arnold
    TARGETED ONCOLOGY, 2022, 17 (06) : 727 - 733
  • [24] Sotorasib: A Review in KRAS G12C Mutation-Positive Non-small Cell Lung Cancer
    Arnold Lee
    Targeted Oncology, 2022, 17 : 727 - 733
  • [25] Concomitant KRAS mutations attenuate sensitivity of non-small cell lung cancer cells to KRAS G12C inhibition
    Vaclova, Tereza
    Chakraborty, Atanu
    Sherwood, James
    Ross, Sarah
    Carroll, Danielle
    Barrett, J. Carl
    Downward, Julian
    de Bruin, Elza C.
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [26] Clinical Characteristics and Outcomes of Patients with BRAF Mutated Non-Small Cell Lung Cancer
    Mu, Y.
    Xing, P.
    Li, Y.
    Hao, X.
    Ying, J.
    Li, J.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S868 - S868
  • [27] Efficacy and safety outcomes in patients receiving sotorasib for advanced KRAS G12C-mutated non-small cell lung cancer
    Milner-Watts, Charlotte
    O'Sullivan, Hazel
    Stewart, James
    Idaikkadar, Praveena
    Tokaca, Nadza
    Davidson, Michael
    Yousaf, Nadia
    Bhosle, Jaishree
    Popat, Sanjay
    O'Brien, Mary
    Minchom, Anna
    LUNG CANCER, 2023, 178 : S31 - S32
  • [28] Characteristics and Treatment Outcomes in Advanced-Stage Non-Small Cell Lung Cancer Patients with a KRAS G12C Mutation: A Real-World Study
    Illini, Oliver
    Fabikan, Hannah
    Hochmair, Maximilian Johannes
    Weinlinger, Christoph
    Krenbek, Dagmar
    Brcic, Luka
    Setinek, Ulrike
    Terbuch, Angelika
    Absenger, Gudrun
    Konjic, Selma
    Valipour, Arschang
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (14)
  • [29] Sotorasib in KRAS G12C-mutated non-small cell lung carcinoma
    Lorenz, Judith
    PNEUMOLOGIE, 2023, 77 (11): : 846 - 846
  • [30] Survival of patients with KRAS G12C mutated stage IV non-small cell lung cancer with and without brain metastases treated with immune checkpoint inhibitors
    Swart, Esther M.
    Noordhof, Anneloes L.
    Damhuis, Ronald A. M.
    Kunst, Peter W. A.
    De Ruysscher, Dirk K. M.
    Hendriks, Lizza E. L.
    van Geffen, Wouter H.
    Aarts, Mieke J.
    LUNG CANCER, 2023, 182
12345